Virtuix Holdings Inc. has entered a strategic partnership with Sirica Therapeutics to deploy its Omni One platform for immersive autism therapy applications. The collaboration aims to enhance engagement and treatment outcomes for children with autism and related disorders using movement-centered virtual reality and AI-assisted therapeutic experiences. This partnership supports Sirica's plan to establish approximately 100 Sirica Centers across the United States, creating a nationwide network of specialized autism treatment facilities.

As part of the initial deployment, Virtuix has sold and shipped the first two Omni One systems to Sirica's treatment center in the San Francisco Bay Area. The partnership builds on Virtuix's ongoing research collaborations with Rutgers University and Florida Gulf Coast University, focusing on AI-assisted neurodivergent therapy and neurological rehabilitation. These initiatives align with Virtuix's strategy to expand its immersive simulation platform into clinical environments.

The collaboration leverages Rutgers University research to advance the application of movement-based technologies in healthcare. Virtuix aims to extend its reach into clinical settings where its technologies may improve patient engagement and therapy efficacy. Sirica's nationwide expansion plan underscores the scalability of the Omni One platform in addressing autism treatment needs.

Partnership Details

Strategic Context

Virtuix's partnership with Sirica follows its research collaborations with Rutgers University and Florida Gulf Coast University. These efforts highlight the company's focus on integrating its full-body simulation systems into healthcare applications. The Omni One platform is designed to support movement-based therapies, which may offer new avenues for treating neurodivergent conditions and neurological disorders.

Emerging Growth Research has reiterated its Buy-Emerging rating and 12-month price target of $9.00 per share for Virtuix Holdings Inc., representing approximately 177% upside from the company's July 1, 2026 closing price of $3.25. The research firm's Fiscal Q4 2026 Quarterly Update highlights a transformational fiscal year for Virtuix, noting that the company exceeded expectations on both revenue and earnings during the quarter while continuing to execute its long-term strategy across consumer virtual reality and defense markets.

The report emphasizes Virtuix's market-leading, patent-protected technology platform, expanding recurring software revenue, growing defense opportunities, and strategic partnership with Meta. Emerging Growth Research believes Virtuix remains one of the most compelling long-term growth opportunities in the emerging virtual reality sector.

Transformational Fiscal 2026 Performance

Fiscal 2026 marked an important milestone for Virtuix as the company continued executing its long-term growth strategy. Fourth quarter revenue increased 32% sequentially, reflecting continued customer adoption despite challenging year-over-year comparisons related to fulfillment of a large preorder backlog in the prior year. Emerging Growth Research believes current financial results establish a strong foundation for accelerating growth in fiscal 2027 and beyond.

Consumer and Defense Growth Strategy

Virtuix continues building a diversified growth platform across both consumer entertainment and defense applications. During the quarter, the company expanded its distribution through a new partnership with Meta, providing access to approximately 20 million Meta Quest headset owners while also growing its presence in Europe and Canada. On the defense side, Virtuix continues advancing its AI-powered Virtual Terrain Walk platform following selection by the U.S. Air Force SBIR program, while management is evaluating strategic defense acquisitions to accelerate government contracting opportunities.

Financial Outlook and Valuation

Emerging Growth Research continues to forecast approximately 15% revenue growth during fiscal 2027 followed by nearly 290% growth during fiscal 2028 as consumer adoption accelerates and defense opportunities begin contributing meaningfully to results. The research firm believes VTIX shares remain substantially undervalued based on both discounted cash flow analysis and peer valuation multiples, supporting the $9.00 per share price target.